- In March 2026, Mirion Technologies announced that its Crew Active Dosimeters will travel in astronauts’ pockets on NASA’s Artemis II mission, providing personal, time-resolved radiation monitoring on the program’s first crewed, approximately 10-day lunar flyby.
- This follow-on role after Artemis I highlights Mirion’s specialist position in space-grade radiation safety, extending its technology beyond traditional nuclear and healthcare settings.
- Next, we’ll examine how Mirion’s Artemis II radiation monitoring role could influence its investment narrative around specialized detection and monitoring solutions.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 26 companies in the world exploring or producing it. Find the list for free.
Mirion Technologies Investment Narrative Recap
To own Mirion Technologies, you need to believe in long term demand for highly specialized radiation detection across nuclear, medical, and now space applications. The Artemis II dosimeter role reinforces Mirion’s brand in critical safety use cases, but it does not materially change the current key catalyst, which is execution on its growing backlog and digital offerings, nor the main risk, which remains exposure to policy and demand swings in its core nuclear markets.
Among recent announcements, Mirion’s selection to supply radiation monitoring and instrumentation systems for TerraPower’s Natrium reactor project looks most connected to the Artemis II news, since both underline Mirion’s position in advanced, safety critical environments. Together, these wins sit alongside its new AI and digital initiatives as potential supports for its narrative around higher value detection and monitoring solutions, even as investors weigh concentration risks in traditional nuclear against expansion into adjacent sectors.
Yet while these wins are encouraging, investors should still be aware of the longer term risk that...
Read the full narrative on Mirion Technologies (it's free!)
Mirion Technologies’ narrative projects $1.3 billion revenue and $138.0 million earnings by 2029.
Uncover how Mirion Technologies' forecasts yield a $28.80 fair value, a 52% upside to its current price.
Exploring Other Perspectives
Four members of the Simply Wall St Community place Mirion’s fair value between US$17.35 and US$28.80, showing how far individual views can stretch. Against this wide spread, the reliance on nuclear sector demand concentration remains a key issue that could shape how those differing expectations play out over time, so it is worth weighing several of these viewpoints before deciding how Artemis II truly fits into Mirion’s story.
Explore 4 other fair value estimates on Mirion Technologies - why the stock might be worth as much as 52% more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Mirion Technologies research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Mirion Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirion Technologies' overall financial health at a glance.
Looking For Alternative Opportunities?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Find 62 companies with promising cash flow potential yet trading below their fair value.
- Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com